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Abstract
Although interferon-λ [also known as type III interferon or interleukin-28 (IL-28)/IL-29] restricts 
infection by several viruses, its inhibitory mechanism has remained uncertain. We used 
recombinant interferon-λ and mice lacking the interferon-λ receptor (IFNLR1) to evaluate the 
effect of interferon-λ on infection with West Nile virus, an encephalitic flavivirus. Cell culture 
studies in mouse keratinocytes and dendritic cells showed no direct antiviral effect of exogenous 
interferon-λ, even though expression of interferon-stimulated genes was induced. We observed no 
differences in West Nile virus burden between wild-type and Ifnlr1−/− mice in the draining lymph 
nodes, spleen, or blood. We detected increased West Nile virus infection in the brain and spinal 
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cord of Ifnlr1−/− mice, yet this was not associated with a direct antiviral effect in mouse neurons. 
Instead, we observed an increase in blood-brain barrier permeability in Ifnlr1−/− mice. Treatment 
of mice with pegylated interferon-λ2 resulted in decreased blood-brain barrier permeability, 
reduced West Nile virus infection in the brain without affecting viremia, and improved survival 
against lethal virus challenge. An in vitro model of the blood-brain barrier showed that interferon-
λ signaling in mouse brain microvascular endothelial cells increased transendothelial electrical 
resistance, decreased virus movement across the barrier, and modulated tight junction protein 
localization in a protein synthesis– and signal transducer and activator of transcription 1 
(STAT1)–independent manner. Our data establish an indirect antiviral function of interferon-λ in 
which noncanonical signaling through IFNLR1 tightens the blood-brain barrier and restricts viral 
neuroinvasion and pathogenesis.
Introduction
Interferon-λ (IFN-λ) belongs to a family of cytokines that signal through the heterodimeric 
IFN-λ receptor, IFNLR, which is composed of interleukin-10 receptor β (IL-10Rβ) and 
IFNLR1 (IL-28Rα). Analogous to signaling by IFN-α/β and its heterodimeric receptor, 
IFNAR, binding of IFN-λ to IFNLR initiates a Janus kinase–signal transducer and activator 
of transcription (JAK-STAT) signaling cascade that induces expression of genes with 
antiviral and immunomodulatory activities (1). Mice lacking IFNLR1 (Ifnlr1−/−) do not 
respond to IFN-λ but retain relatively normal responses to IFN-α/β (2). In contrast to 
IL-10Rβ, which is expressed more widely, IFNLR1 exhibits a cell type–restricted expression 
pattern (3, 4). IFNLR1 is expressed preferentially on epithelial cells, and inhibitory effects 
of IFN-λ in vivo have been documented against viruses that target epithelial tissues (4–8). In 
cell culture, IFN-λ reportedly inhibits infection of a broader panel of viruses, including West 
Nile virus (WNV) (9).
WNV is an encephalitic flavivirus that cycles in nature between birds and mosquitoes, with 
humans becoming infected as incidental deadend hosts. About 20% of infected humans 
develop a febrile illness, and a subset of these progress to severe neuroinvasive disease (10). 
Among hospitalized patients, the case fatality rate is 5 to 10%, and survivors are commonly 
left with debilitating neurologic sequelae.
Because WNV is highly neurovirulent, the failure of infections to progress uniformly to 
neurologic disease suggests that barriers to neuroinvasion exist and that dissemination into 
the central nervous system (CNS) determines clinical outcome. The precise mechanisms by 
which WNV spreads to the brain and spinal cord remain unclear (11), but neuroinvasion 
likely occurs by a hematogenous route. Thus, the blood-brain barrier (BBB) represents a key 
defense against WNV neuroinvasion (12). The BBB is composed of tight junctions between 
endothelial cells of the CNS microvasculature and the end-feet of astrocytes; the endothelial 
cells and astrocytes are further separated by two basement membranes and a perivascular 
space. BBB permeability is increased in response to proinflammatory stimuli, including 
lipopolysaccharide (LPS), tumor necrosis factor–α (TNF–α), and IFN-γ, and this opening 
also permits trafficking of immune cells into the CNS (13, 14). Although BBB opening may 
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be necessary to resolve certain CNS infections, it is regulated to avoid pathological 
consequences from infiltrating cells or other substances from the periphery (12).
Although some inflammatory stimuli increase BBB permeability, IFN-α/β may enhance 
BBB integrity. IFN-β treatment reduces endothelial permeability in an in vitro model of the 
BBB (14, 15) and is used therapeutically to treat multiple sclerosis, which features BBB 
breakdown and trafficking of autoreactive T cells into the CNS as key components of the 
disease pathology (16). In tissue culture, IFN-β directly regulates endothelial permeability 
and tight junction formation via the actions of the GTPases (guanosine triphosphatases) 
Rac1 and RhoA (14). Given the analogous JAK-STAT–dependent signaling pathways 
induced by IFN-α/β and IFN-λ, we evaluated the antiviral effects of IFN-λ on WNV 
infection. Our results suggest that IFN-λ signaling inhibits WNV infection of the CNS by 
modulating endothelial cell tight junction integrity, which decreases BBB permeability, 
restricts virus neuroinvasion, and prevents lethal infection.
Results
IFN-λ does not inhibit WNV infection of relevant target cells
Given that IFN-λ reportedly induces an antiviral gene program similar to IFN-α/β (17–19), 
we tested whether it would inhibit WNV infection in cell culture. We expected IFN-λ to 
exert its greatest effects on epithelial cells because of the reported tissue-specific expression 
pattern of Ifnlr1 (3–5). Before assaying for direct antiviral effects, we assessed the relative 
mRNA expression of the receptors for IFN-α/β (Ifnar1) and IFN-λ (Ifnlr1 and Il10rb) in 
primary cells: cortical neurons and bone marrow–derived dendritic cells (DCs) and 
macrophages (Fig. 1, A to D).We also tested a mouse keratinocyte cell line because 
keratinocytes are one of the few epithelial cells targeted by WNV in vivo (20). All cell types 
expressed Ifnar1, whereas Il10rb was detected in keratinocytes, DCs, and macrophages, but 
not cortical neurons. We detected Ifnlr1 expression in keratinocytes and DCs, but expression 
in macrophages and cortical neurons was near the limit of detection. As expected, Ifnlr1 
expression was not detected in cells from Ifnlr1−/− mice.
On the basis of Ifnlr1 mRNA expression, we chose keratinocytes and DCs for further 
studies. We treated cells with IFN-λ3 or IFN-β for 6 hours and measured IFN-stimulated 
gene (ISG) expression by quantitative reverse transcription polymerase chain reaction (qRT-
PCR). Ifit1 and Rsad2 were up-regulated in response to IFN-λ3 or IFN-β (Fig. 1, E and F), 
although induction was lower with IFN-λ than IFN-β. For example, in keratinocytes, IFN-β 
(0.1 ng/ml) increased Ifit1 mRNA expression by ∼1700-fold, whereas IFN-λ (100 ng/ml) 
produced a <150 fold increase (Fig. 1E). The effect of IFN-λ on ISG expression was less 
potent in DCs compared to keratinocytes and was absent in Ifnlr1−/− DCs. Although IFN-λ 
induced expression of the ISGs Ifit1 and Rsad2, unlike IFN-β, it did not stimulate expression 
of Irf7 (Fig. 1G). An increase in the IFN-λ dose to 1000 ng/ml failed to increase ISG 
expression further (Fig. 1H).
We extended these results using RNA-seq (RNA sequencing) analysis to obtain a profile of 
the IFN-λ gene signature in primary DCs (Fig. 1I). Using a threefold induction cutoff 
(relative to mock) after 6 hours of IFN treatment, we detected induction of 208 genes in 
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IFN-β–treated DCs, whereas no genes were induced to this level in the IFN-λ–treated DCs 
(table S1). We also did not detect any ISGs that were induced uniquely by IFN-λ; the IFN-
λ– stimulated genes were a subset of those induced by IFN-β.
To assess whether the gene program induced by IFN-λ inhibited WNV replication, we 
treated keratinocytes and DCs with IFN-λ3 or IFN-β before infection. In keratinocytes, we 
observed a dose-dependent inhibition of viral replication by IFN-β (Fig. 2A). In both wild-
type and Ifnlr1−/− DCs, even the lower dose of IFN-β blocked WNV infection (Fig. 2, B and 
C). We did not observe any inhibition of WNV replication by IFN-λ3, even at doses that 
induced ISGs. We performed multistep viral growth analyses in primary cells from Ifnlr1−/− 
and wild-type mice and found no differences in WNV infection between Ifnlr1−/− and wild-
type DCs, macrophages, or cortical neurons (Fig. 2, D to F). Our results suggest that 
although IFN-λ induced expression of ISGs, the effect was not directly antiviral. This may 
be because either the magnitude of the response was insufficient or the specific set of genes 
induced was not inhibitory against WNV.
IFN-λ signaling limits WNV neuroinvasion
We assessed a role for IFN-λ in restricting WNV infection in vivo. We infected wild-type 
and Ifnlr1−/− mice and measured viral burden in tissues. Wild-type and Ifnlr1−/− mice 
displayed no significant differences in viral loads at any time point in peripheral tissues, 
including the serum, draining lymph nodes, spleen, and kidney (Fig. 3, A to D). However, 
Ifnlr1−/− mice sustained higher viral titers in the brain and spinal cord at days 6 and 8 after 
infection (Fig. 3, E and F). We also detected virus in the brain earlier in a subset of Ifnlr1−/− 
mice compared to wild-type mice (two of eight Ifnlr1−/−mice positive at day 4 after 
infection, compared to zero of five wild-type mice).
To determine whether the higher WNV titers in the CNS of Ifnlr1−/− mice reflected a direct 
antiviral effect of IFN-λ in brain tissues, we infected mice by an intracranial route and 
measured viral titers 3 and 5 days after infection. We found no difference in viral titer 
between wild-type and Ifnlr1−/−mice in any of the CNS regions examined (Fig. 3, G to I). 
Thus, although Ifnlr1−/− mice developed enhanced CNS infection after peripheral WNV 
infection, no increase was observed when the virus was inoculated directly into the brain.
Ifnlr1−/− mice develop normal adaptive immune responses to WNV infection
We considered whether IFN-λ might restrict WNV neuroinvasion indirectly by regulating 
adaptive immune responses, which are required to prevent dissemination to the CNS (21). 
However, we detected no difference in serum concentrations of anti-WNV immunoglobulin 
M (IgM) or IgG at days 4, 6, or 8 after WNV infection between wild-type and Ifnlr1−/− mice 
(fig. S1). To assess cellular immune responses, we profiled leukocytes from the spleen and 
brain at 8 days after WNV infection and found no differences between wild-type and 
Ifnlr1−/− mice in total numbers or percentages of CD11b+, CD11c+, CD4+, or CD8+ cells 
(Fig. 4, A to D and K to N). Antigen-specific CD8+ T cell responses were equivalent 
between wild-type and Ifnlr1−/− mice (Fig. 4, E and O), and effector functions (production 
of granzyme B, IFN-γ, and TNF-α) also were similar between wild-type and Ifnlr1−/−mice 
in both the spleen and the brain (Fig. 4, F to J and P to T).
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Ifnlr1−/− mice have increased BBB permeability after WNV infection
Because IFN-α/β signaling can enhance BBB integrity (14), we hypothesized that IFN-λ 
might exert an analogous effect to prevent virus transport across the BBB, which could 
explain the increased CNS infection observed in Ifnlr1−/− mice. We assessed BBB 
permeability in wild-type and Ifnlr1−/− mice 4 days after WNV infection. Compared to 
mock-infected mice, WNV infection resulted in increased extravasation of sodium 
fluorescein dye from the peripheral circulation into the CNS (Fig. 5, A to C). Although 
Ifnlr1−/− mice showed no basal differences in BBB permeability compared to wild-type 
mice, the WNV-induced permeability change was greater in Ifnlr1−/− mice, suggesting that 
IFN-λ signaling may tighten the barrier in response to infection. As an independent measure 
of BBB permeability, we assessed leakage of endogenous IgG into the brain parenchyma 
after WNV infection (14). Although minimal IgG was detected in the brains of uninfected 
mice, IgG accumulation became apparent at 4 days after infection, and Ifnlr1−/− mice 
exhibited greater leakage than did wild-type mice (Fig. 5, D and E). Thus, in the context of 
WNV infection, the BBB of Ifnlr1−/− mice was more permeable to both small molecules and 
proteins. Given that inflammatory cytokines, including IFN-γ and TNF-α, promote BBB 
opening (14, 22), we considered whether the increased permeability in Ifnlr1−/− mice was 
due to elevated cytokine production. We measured concentrations of 21 cytokines in serum 
at 3 and 5 days after infection and found no differences between wild-type and Ifnlr1−/− 
mice (table S2). We also assessed IFN-α/β activity in the serum and found no differences 
between WNV-infected wild-type and Ifnlr1−/− mice (fig. S2).
IFN-λ signaling improves endothelial barrier integrity in vitro
To explore how IFN-λ signaling modulates WNV entry into the CNS, we used an in vitro 
model of the BBB (14, 23). In this system, brain microvasculature endothelial cells 
(BMECs) were cultured in the upper chamber of a Transwell insert, with supporting 
astrocytes in the lower chamber. Transendothelial electrical resistance (TEER) across the 
BMEC monolayer indicated endothelial monolayer integrity, with higher resistance 
representing a tighter barrier. We first measured expression of IFN receptors and WNV 
replication in the two primary cell typesin this system. BMECs and astrocytes expressed 
abundant Ifnar1 and Il10rb mRNA, whereas Ifnlr1 mRNA expression was low (Fig. 6, A 
and B). We found no difference in WNV replication in BMECs and astrocytes prepared 
from wild-type and Ifnlr1−/− mice (Fig. 6, C and D).
We next infected Transwell cultures of BMECs with WNV and measured TEER after 6 
hours, a time point that precedes de novo spread of WNV infection (24). Although wild-type 
and Ifnlr1−/− BMECs exhibited equivalent TEER in the absence of infection, the increase in 
TEER after WNV infection was blunted in Ifnlr1−/− cells (Fig. 6E). The effect of IFN-λ was 
due to signaling in BMECs rather than astrocytes; in reciprocal culture experiments, only 
Ifnlr1−/− BMECs exhibited the lower TEER phenotype regardless of the astrocyte genotype 
(Fig. 6E). Therefore, subsequent Transwell experiments used wild-type astrocytes paired 
with wild-type or Ifnlr1−/− BMECs.
We next treated BMECs with recombinant murine IFNs for 6 hours and measured TEER. 
IFN-λ3 produced a dose-dependent increase in TEER at 6 hours, and this effect was 
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abolished in Ifnlr1−/− BMECs (Fig. 6F). As observed previously (14, 15), IFN-β treatment 
produced an increase in TEER. However, this effect was diminished in Ifnlr1−/−BMECs, 
suggesting that a portion of the IFN-β effect may be due to IFN-λ signaling. To distinguish 
the contributions of IFN-α/β and IFN-λ to the WNV-induced TEER increase, we pretreated 
BMECs with a blocking monoclonal antibody against IFNAR1 (25). When IFN-α/β 
signaling was blocked, WNV infection did not produce an increase in TEER in either wild-
type or Ifnlr1−/− BMECs (Fig. 6G). These results suggest that IFN-λ signaling promotes 
endothelial barrier tightening and that IFN-λ production after WNV infection requires IFN-
α/β signaling, as opposed to being induced directly by pattern recognition receptor signaling 
pathways.
Because it remained possible that the IFN-λ signaling effect on TEER was mediated by an 
induced cytokine, we tested the requirement for de novo protein synthesis. BMECs were 
pretreated with the protein synthesis inhibitor cycloheximide and then infected with WNV 
or treated with IFN-β or IFN-λ3 for 6 hours. When cycloheximide was added, the WNV-
induced increase in TEER was abolished and the IFN-β–induced increase was diminished 
(Fig. 6H). Cycloheximide treatment had no effect on the increase in TEER produced by 
IFN-λ3, indicating that BMECs could form a tighter barrier downstream of IFN-λ–IFNLR 
signaling without requiring de novo protein synthesis.
To define further the signaling pathway by which IFN-λ regulates TEER changes in 
BMECs, we assessed mRNA expression of Ifnb, Ifna, and Il28b in BMECs after treatment 
with IFN-β, IFN-λ3, or LPS for 6 hours. We did not detect expression of these IFNs, 
although the ISGs Ifit1 and Rsad2 were induced (fig. S3). Given the results from the 
cycloheximide experiments (Fig. 6H), we hypothesized that the IFN-λ–induced TEER 
response might occur through a noncanonical signaling pathway that did not require ISG 
expression. To evaluate this, we prepared BMECs from wild-type and Stat1−/− mice and 
measured TEER after treatment with IFN-β or IFN-λ3. Both IFN-l and IFN-β induced 
increases in TEER within 2 hours of treatment in a STAT1-independent manner (Fig. 6I). At 
later time points (for example, 12 hours), TEER values were lower in Stat1−/− cells 
compared to wild-type cells, indicating a subordinate role for canonical STAT1 signaling 
and possibly ISG expression in barrier tightening. To determine whether IFN-λ also could 
induce endothelial barrier tightening in human cells, we treated a human BMEC cell line 
(HCMEC/D3) (23) in a Transwell insert with pegylated human IFN-λ1 or human IFN-β and 
measured TEER over time (Fig. 6J). Within 2 hours of IFN treatment, TEER increased 
markedly, demonstrating analogous effects of IFN-λ on mouse and human BMECs. Our 
experiments suggest a model in which WNV infection stimulates the production of IFN-λ, 
possibly downstream of IFN-α/β signaling. Along with IFN-α/β signaling through IFNAR 
(14), circulating IFN-λ would signal through IFNLR on BMECs via a noncanonical STAT1-
independent and protein synthesis–independent pathway to tighten the endothelial barrier 
and limit viral neuroinvasion.
We questioned whether changes in TEER directly affected transit of WNV across the 
endothelial barrier. We treated HCMEC/D3 cells first with LPS for 18 hours, and then with 
IFN-λ1 for 6 hours. We then added WNV to the upper chamber and, after 6 hours, measured 
virus that had crossed into the lower chamber. As expected, we observed decreased TEER 
Lazear et al. Page 6













after LPS treatment and an increase in TEER in response to IFN-λ treatment (Fig. 6K). 
Consistent with the changes in TEER, LPS treatment resulted in greater crossing of WNV 
into the lower chamber, and this effect was diminished by IFN-λ treatment (Fig. 6L). Thus, 
IFN-λ signaling promotes endothelial barrier tightening, which restricts WNV transit.
To define how IFN-λ modulates TEER, we analyzed the location of the endothelial cell 
junction proteins ZO-1 and claudin-5 in BMECs and mouse brain sections after treatment 
with LPS and IFN-λ (Fig. 7). Whereas colocalization of ZO-1 and claudin-5 was observed in 
mock-treated BMECs, treatment with LPS, which disrupts BBB integrity (13), caused ZO-1 
and claudin-5 to dissociate. The effect of LPS on cell junction protein colocalization was 
reversed by IFN-λ3 treatment (Fig. 7, A and B). We observed a similar effect in the brains 
of mice treated with LPS and pegylated IFN-λ2 (Fig. 7C).
IFN-λ enhances BBB integrity in vivo
Given that Ifnlr1−/− mice displayed increased BBB permeability after WNV infection and 
IFN-λ decreased the barrier function of BMECs in vitro, we hypothesized that 
administration of IFN-λ might restrict BBB permeability in vivo. We treated wild-type mice 
with LPS to open the BBB and then administered pegylated murine IFN-λ2 or PBS. LPS 
treatment increased BBB permeability compared to PBS, but this effect was diminished in 
mice receiving IFN-λ2 (Fig. 8, A to C).
We next tested whether administration of IFN-λ could restrict WNV neuroinvasion. Wild-
type mice were inoculated subcutaneously with WNV, and pegylated murine IFN-λ2 was 
administered via an intravenous route on the day of infection as well as 2 and 4 days 
afterward. Consistent with data from Ifnlr1−/− mice (Fig. 3A), IFN-λ2 treatment did not 
exhibit a direct antiviral effect, because viremia remained unchanged (Fig. 8D). 
Nonetheless, IFN-λ 2–treated mice showed improved survival rates compared to PBS-
treated controls (Fig. 8E). To determine whether the improved survival observed in IFN-λ2–
treated mice correlated with reduced WNV neuroinvasion, we measured viral burden in the 
CNS. Wild-type mice were inoculated with WNV and treated with pegylated murine IFN-λ2 
at days 2, 3, and 4 after infection. As expected, IFN-λ2 treatment did not reduce viremia 
(Fig. 8F), but at day 8 after infection, IFN-λ2–treated mice had lower virus titers in the 
cerebral cortex compared to control mice that received PBS (Fig. 8G). This effect was 
region-specific, because reductions in virus titer were not observed in the cerebellum or 
spinal cord.
Discussion
Previous studies in Ifnlr1−/− mice revealed a role for IFN-λ in controlling viral infection in 
epithelial tissues, although no inhibitory effect was observed with several viruses that 
disseminate more broadly (2, 4, 5, 7, 8, 26). These observations were consistent with a 
preferential epithelial cell expression pattern for IFNLR1 (3, 4) and tissue responsiveness to 
treatment with exogenous IFN-λ (3, 5–7). Although WNV replicates in many cell types in 
vitro, its main targets in vivo are myeloid cells and neurons (21). Because WNV is not 
reported to target epithelial cells other than keratinocytes in the skin (20), a virologic 
phenotype for WNV in the CNS of Ifnlr1−/− mice was unexpected. Our experiments show 
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that IFN-λ signaling did not directly inhibit WNV infection in vitro or in vivo, but instead 
indicate that IFN-λ signaling enhances the integrity of the BBB, thereby limiting the 
neuroinvasive potential of WNV.
Although IFN-α/β directly stimulates expression of genes that inhibit WNV and other 
flaviviruses (27), in our experiments, IFN-λ failed to do so in several cell types in culture, 
even though the receptors were expressed and ISGs were induced. Although a previous 
study reported an antiviral effect of IFN-λ on WNV (9), those observations may not be 
comparable, because they were based on luciferase production by WNV replicons in human 
tumor cell lines, as opposed to our study, which measured replication of fully infectious 
virus in primary mouse cells and a mouse cell line.
Why did we not observe a direct inhibitory effect of IFN-λ in our experiments? On the basis 
of RNA-seq and qRT-PCR analyses, the magnitude and breadth of the ISG response to IFN-
λ were reduced compared to IFN-β. Although previous studies have compared the 
transcriptional signatures induced by IFN-λ and IFN-α/β (17–19, 28), these studies were 
performed in human tumor cell lines. Our analysis compared the transcriptional profiles 
induced by IFN-λ and IFN-β in mouse DCs and may help to explain the results of other viral 
pathogenesis studies in Ifnlr1−/− mice. The ability of IFN-λ to induce ISG expression in a 
more targeted set of cells compared to IFN-α/β suggests a possible therapeutic application in 
which IFN-λ would provide a more focused antiviral or immunomodulatory effect with 
fewer side effects (26, 29).
We observed increased WNV infection in the brain and spinal cord of Ifnlr1−/− mice. 
Because our experiments failed to show a direct antiviral effect of IFNLR1 in neurons, we 
hypothesized that IFN-λ signaling might minimize WNV spread to the CNS by affecting 
BBB permeability. The following observations support a model in which IFN-λ signaling 
restricts the neuroinvasive potential of WNV by improving BBB function: (i) BBB 
permeability was greater in WNV-infected Ifnlr1−/− compared to wild-type mice; (ii) wild-
type and Ifnlr1−/− mice had equivalent viral burden in peripheral tissues, so the increased 
infection in the brain was not due to antiviral effects of IFN-λ in the periphery; (iii) 
proinflammatory cytokine levels were similar in wild-type and Ifnlr1−/− mice and thus did 
not cause differential changes in BBB permeability; (iv) TEER was lower in WNV-infected 
Ifnlr1−/− BMECs compared to wild-type cells; (v) TEER was higher after treatment of wild-
type BMECs or HCMEC/D3 cells with exogenous IFN-λ; (vi) IFN-λ treatment restricted 
transit of WNV across HCMEC/D3 monolayers; (vii) treatment of mice with IFN-λ 
minimized BBB permeability changes associated with LPS administration; and (viii) 
treatment of mice with IFN-λ decreased WNV infection in the brain without altering 
viremia, and this was associated with improved survival rates. We readily observed BBB 
tightening effects of IFN-λ even in the context of intact IFN-α/β responses. Circulating IFN-
λ produced in response to infection may serve a protective role by limiting virus transit into 
the CNS and countering the effects of inflammatory cytokines that increase BBB 
permeability (for example, TNF-α, IL-1β, or IFN-γ) (14, 22, 23).
How does IFN-λ signaling affect BBB permeability and limit WNV neuroinvasion? Unlike 
some viruses, which infect peripheral neurons and then enter the CNS by retrograde 
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trafficking, WNV likely enters the CNS via the bloodstream (12). Neuroinvasion by this 
hematogenous route could occur through trafficking of infected cells across the BBB, 
transcellular or paracellular transit of virus across the cells of the BBB, or direct infection of 
BBB cells (11, 12). Because we saw no effect of IFNLR1 expression on WNV replication in 
BMECs or on trafficking of immune cells into the CNS, our data suggest a model in which 
WNV virions transit through BBB cell junctions and IFN-λ signaling limits this. Indeed, 
IFN-λ treatment inhibited the accumulation of viral RNA on the basal side of an 
HCMEC/D3 monolayer within6 hours of exposure to WNV. The effect of IFN-λ occurred 
via a noncanonical STAT1- and protein synthesis–independent signaling pathway. IFN-λ 
signaling enhanced colocalization of the cell junction proteins ZO-1 and claudin-5 under 
conditions of inflammation in vitro and in vivo, which tightened the endothelial barrier. 
Because the rapid effect of IFN-λ preceded completion of the viral replication cycle (24), the 
phenotype was not due to the spread of infection through the cell culture, but rather to 
cellular responses induced rapidly in response to pathogen sensing. Indeed, previous studies 
demonstrated that active viral replication was not required for endothelial barrier tightening 
(14).
As mosquitoes inoculate WNV beneath the epidermis, the BBB may represent one of the 
first physical barriers encountered by WNV as it spreads in a vertebrate host. Modulation of 
physical barriers to infection is a previously undescribed antiviral mechanism for IFN-λ. 
Barrier tightening by IFN-λ signaling also may restrict dissemination of viruses that transit 
across epithelial surfaces, including the skin, lungs, and gastrointestinal tract. Because many 
viruses use cell junction proteins as entry receptors (30), some of the antiviral effects of 
IFN-λ observed in other viral systems (26) may be explained by relocalization of viral entry 
receptors.
Although our experiments demonstrated a BBB tightening effect of IFN-λ on both human 
and murine BMECs in culture, one limitation of these studies is that we did not analyze the 
effects of the different IFN-λ subtypes. Mice encode two functional IFN-λ genes (IFN-λ2 
and IFN-λ3), and humans have four paralogs (IFN-λ1, 2, 3, and 4). Whereas IFN-λ2 and 
IFN-λ3 are nearly identical (1), IFN-λ1 and IFN-λ4 may have distinct properties; a 
polymorphic allele that enables IFN-λ4 production is associated with impaired hepatitis C 
virus clearance (31). Because of the limited types of recombinant proteins available, we 
were unable to assess whether IFN-λ subtypes vary in their BBB tightening activity.
In summary, our results suggest a new function of IFN-λ, whereby signaling through 
IFNLR1 rapidly modulates endothelial cell junctions without a requirement for STAT1 
signaling or protein synthesis. This results in a tighter BBB, which restricts pathogen entry 
into the CNS parenchyma. In humans, multiple polymorphisms in the IFN-λ locus are 
associated with differential clearance of hepatitis B and C viruses (31), as well as the 
severity of herpesvirus infections (32, 33). Further analysis is warranted to define similar 
genetic linkages to neuroinvasive infections or CNS autoimmune diseases. Such information 
may provide new contexts for therapeutic interventions with IFN-λ.
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We initiated this study to determine whether IFN-λ controls WNV pathogenesis. Our initial 
observation was that Ifnlr1−/− mice had increased viral burden in the CNS, and subsequent 
experiments evaluated why this occurred. We measured viral titers in tissues and replication 
in primary cells. We assessed immunologic parameters including antibody and cytokine 
concentrations in serum and leukocyte phenotypes in the spleen and brain. After excluding 
antiviral or immunomodulatory effects of IFN-λ, we considered whether increased 
neuroinvasion might be due to altered BBB permeability. We used an in vitro model of the 
BBB, in which resistance across a mouse or human endothelial cell monolayer corresponded 
to barrier tightness. Sample sizes and endpoints were selected on the basis of our experience 
with these systems. Mice were age- and sex-matched between groups. Investigators were not 
blinded when conducting or evaluating the experiments, and no randomization process was 
performed.
Viruses
WNV strain 3000.0259 was isolated in New York in 2000 and passaged once in C6/36 cells. 
Virus titers were measured by plaque assay on BHK21-15 cells (34).
Mouse experiments
C57BL/6 wild-type mice were obtained commercially (Jackson Laboratories) or bred in-
house. Stat1−/− mice (35) were provided by H. Virgin (Washington University). Ifnlr1−/− 
mice (originally called IL-28RA−/−, obtained from Bristol-Myers Squibb) lack the entire 
Ifnlr1 coding sequence (2). Five- to 12-week-old wild-type and Ifnlr1−/− mice were used for 
in vivo studies, as indicated in the figure legends. For peripheral infection, 102 PFU of 
WNV in 50 ml was inoculated subcutaneously into the footpad. For intracranial infection, 
101 PFU of WNV in 25 μl was injected into the right cerebral hemisphere. Experiments 
were approved and performed in accordance with Washington University Animal Studies 
Guidelines.
Cells
Macrophages, DCs, cortical neurons, BMECs, and astrocytes were generated from wild-type 
or Ifnlr1−/− mice as described (14, 23, 36). The human BMEC cell line HCMEC/D3 was 
cultured as described (23). The mouse keratinocyte cell line PDV was purchased (Cell Lines 
Service) and cultured in DMEM (Dulbecco's modified Eagle's medium) supplemented with 
10% fetal bovine serum, L-glutamine, and non-essential amino acids.
IFN treatment and viral infection of cells Keratinocytes and DCs were treated with 
recombinant murine IFN-λ3 (0.1 to 1000 ng/ml) or IFN-β (0.1 or 1 ng/ml) (PBL Assay 
Science) for 6 hours and then infected with WNV at an MOI of 0.1. Supernatants were 
titered by focus-forming assay (34). Gene expression was analyzed 6 hours after IFN 
treatment. Total RNA was isolated using an RNeasy Mini Kit (Qiagen), and fluorogenic 
qRT-PCR was performed using One-Step RT-PCR Master Mix and a 7500 Fast Real-Time 
PCR System (Applied Biosystems). Gene expression was measured using the indicated 
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TaqMan reagents (Integrated DNA Technologies) (table S3). Multistep virus growth 
analysis was performed after infection at an MOI of 0.01 for macrophages, astrocytes, and 
BMECs, or 0.001 for DCs and cortical neurons. Viral infection was measured by a focus-
forming assay (34).
RNA-seq analysis
DCs were generated from wild-type mice and treated with serum-free medium (mock), IFN-
β (20 ng/ml), or IFN-λ3 (10 ng/ml) for 6 hours. Total RNA was isolated using an RNeasy 
Kit (Qiagen). Samples were multiplexed and barcoded for sequencing on the Illumina HiSeq 
2000. A minimum of 25 million (50–base pair pair-end) reads were generated per sample. 
Sequencing reads were mapped to the mouse genome [National Center for Biotechnology 
Information (NCBI) mm10] using Bowtie (2.10) and Tophat (2.010). Transcript assemblies 
and quantifications (FPKM) were calculated using the Cufflinks package (2.11). Genes with 
larger than threefold differences with IFN treatment (relative to mock) were retained, sorted, 
and displayed in a summarizing heatmap using the Matlab software package.
Tissue viral burden
To monitor viral spread in vivo, mice were infected with 102 PFU of WNV by subcutaneous 
inoculation and sacrificed at specified time points. To monitor viral replication directly in 
the CNS, mice were infected with 101 PFU of WNV by intracranial injection and sacrificed 
at day 3 or 5 after infection. After cardiac perfusion with PBS, organs were harvested and 
virus was titered by plaque assay (34). Viral RNA was isolated from serum and plasma 
using a Viral RNA Mini Kit (Qiagen) and from draining lymph nodes using an RNeasy Mini 
Kit (Qiagen). Viral load was measured by qRT-PCR with the indicated primer and probe 
sequences (table S3).
Antibody responses
WNV-specific IgM and IgG concentrations in serum were determined using an enzyme-
linked immunosorbent assay (ELISA) against purified WNV E protein, as described (37).
Serum type I IFN activity
Concentrations of biologically active type I IFN were determined using a bioassay as 
described (38).
Cytokine analysis
Cytokine concentrations in serum were measured 3 and 5 days after infection using a Bio-
Plex Pro 23-Plex Group I Cytokine Kit (Bio-Rad) and Bio-Plex 200 (Bio-Rad).
Cellular immune responses
Wild-type and Ifnlr1−/− mice were infected subcutaneously with 102 PFU of WNV, and at 8 
days after infection, spleens and brains were harvested after cardiac perfusion with PBS 
(39). Cells were incubated with the following antibodies and processed by flow cytometry 
(LSR II, Becton Dickinson): CD3 (eBioscience, clone 145-2C11), CD4 (Bio-Legend, clone 
RM4-5), CD8a (BioLegend, clone 53-6.7), CD19 (Invitrogen), CD45 (BioLegend, clone 30-
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F11), CD11b (BioLegend, clone M1/70), CD11c (BioLegend, clone N418), granzyme B 
(Invitrogen), IFN-γ (BioLegend, clone XMG1.2), and TNF-α (BioLegend, clone MP6-
XT22). IFN-γ and TNF-α staining was performed after ex vivo restimulation with a Db-
restricted NS4B immunodominant peptide using 1 μM of peptide and brefeldin A (5 μg/ml) 
(Sigma). Flow cytometry data were analyzed using FlowJo software (Tree Star).
BBB permeability measurements and confocal microscopy Eight-week-old mice were 
infected with 102 PFU of WNV or diluent (mock), and BBB permeability was assessed after 
4 days. In other experiments, mice were treated with LPS (List Biological Laboratories, 3 
mg/kg via intraperitoneal injection) and pegylated murine IFN-λ2 (Bristol-Myers Squibb, 25 
μg via intravenous injection), and BBB permeability was assessed 24 hours later. Sodium 
fluorescein dye (100 mg/ml) was administered via intraperitoneal injection in 100 ml. After 
45 min, blood was collected by cardiac puncture into EDTA-coated tubes. Mice were 
perfused and CNS tissues were harvested, homogenized into PBS, clarified by 
centrifugation, precipitated in 1% trichloroacetic acid, and neutralized with borate buffer. 
Fluorescence emission at 485 and 528 nm was determined using the microplate reader 
Synergy H1 and Gen5 software (BioTek Instruments Inc.). Fluorescein concentration was 
calculated from a standard curve, and tissue fluorescence values were normalized to the 
plasma fluorescence values from the same mouse.
Polarized BMECs on chamber slides were treated first with LPS (100 ng/ml) for 18 hours 
and then with murine IFN-λ3 (100 ng/ml) for 6 hours. Cells were fixed in methanol and 
blocked with 10% goat serum. Mice were perfused with PBS and then 4% 
paraformaldehyde. Cryoprotected brains were embedded in O.C.T. medium (Tissue-Tek), 
and 8-mm frozen sections were mounted on slides. Cells and sections were stained with 
primary antibodies against the cell junction proteins ZO-1 (rat monoclonal R40.76, 
Millipore) and claudin-5 (rabbit polyclonal, Invitrogen) followed by Alexa Fluor–
conjugated secondary antibodies. Colocalization of ZO-1 and claudin-5 staining was 
calculated using ImageJ software. Endogenous mouse IgG was detected in brain sections 
using an Alexa Fluor 488 anti-mouse IgG antibody. Nuclei were stained with TO-PRO-3. 
The green channel of individual images was converted to 8-bit grayscale format, and mean 
gray values (sum of gray values in all pixels per total number of pixels) were measured 
using ImageJ software.
Transwell cultures and TEER measurements BMECs and HCMEC/D3 cells were grown 
until fully polarized in Transwell cultures (23). BMECs were grown above astrocyte 
cultures, whereas HCMEC/D3 cells were grown without astrocytes. TEER was measured 
via chopstick electrode with an EVOM volt meter (World Precision Instruments). Resistance 
values are reported as W/cm2, with the resistance value for Transwell inserts with no cells 
subtracted as background. TEER measurements were collected at 6 hours after infection 
with WNV, an MOI of 0.01, or treatment with murine IFN-λ3 (10 or 100 ng/ml), murine or 
human IFN-β (10 ng/ml), or pegylated human IFN-λ1 (100 ng/ml) (Bristol-Myers Squibb); 
mock wells were treated with culture medium. To block IFN-α/β signaling, BMEC cultures 
were treated with the blocking monoclonal antibody MAR1-5A3 (25 μg/ml) (25) for 1 hour 
before infection. A nonbinding monoclonal antibody (GIR-208) was used as an isotype 
control (25). To block de novo protein synthesis, BMEC cultures were pretreated with 
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cycloheximide (20 μg/ml) for 18 hours before treatment with IFN-β or IFN-λ3 or infection 
with WNV. To measure virus transit across the endothelial barrier, HCMEC/D3 cells in 
Transwells were treated first with LPS (100 ng/ml) for 18 hours, and then human IFN-β or 
pegylated human IFN-λ1 (100 ng/ml) for 6 hours. WNV was added to the upper chamber of 
the Transwell at an MOI of 0.01. After 6 hours, virus in the lower chamber was measured by 
qRT-PCR.
Statistical analysis
Tissue titers and immunophenotyping experiments were analyzed by the Mann-Whitney 
test, whereas parametric tests (t test and two-way ANOVA) were used in other experiments. 
Survival was analyzed by the log-rank test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. IFN-λ produces cell type–restricted induction of ISGs
(A to D) Expression of Ifnar1, Ifnlr1, and Il10rb was measured by qRT-PCR from 
uninfected mouse keratinocytes, DCs, macrophages, orcortical neurons. Gene expression 
was normalized to 18S ribosomal RNA (rRNA). Dotted lines indicate the sensitivity of the 
assay. WT, wild type. (E to G) Mouse keratinocytes and DCs were treated with murine IFN-
λ3 or IFN-β for 6 hours. Expression of Ifit1, Rsad2, and Irf7 was measured by qRT-PCR. 
Gene expression was normalized to 18S rRNA and to mock-treated cells. Results represent 
means ± SEM of nine samples from three independent experiments. Dotted lines indicate 
gene expression in mock-treated cells. (H) Mouse keratinocytes were treated with IFN-λ3 
for 6 hours, and expression of Ifit1 was measured by qRT-PCR. Gene expression was 
normalized to Gapdh. The dotted line represents gene expression in mock-treated cells. 
Results represent means ± SEM of 2 to 10 samples from three independent experiments. (I) 
Mouse DCs were treated with IFN-λ3 (10 ng/ml) or IFN-β (20 ng/ml) for 6 hours. Total 
RNA was analyzed by RNA-seq. Genes that were induced or repressed by more than 
threefold (relative to mock-treated) are shown in a heatmap representation.
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Fig. 2. IFN-λ does not directly inhibit WNV infection
(A to C) Mouse keratinocytes and DCs were pretreated with murine IFN-λ3 or IFN-β for 6 
hours and then infected with WNV at a multiplicity of infection (MOI) of 0.1. Viral 
infection was measured by focus-forming assay and expressed as focus-forming units (FFU) 
per milliliter. (D to F) Primary cells prepared from WT or Ifnlr1−/− mice were infected with 
WNV. Results represent means ± SEM of nine samples from three independent experiments. 
Dotted lines indicate the sensitivity of the assay. Viral titers in IFN- treated cells were 
compared to mock-treated cells [two-way analysis of variance (ANOVA)]. (A) **P = 
0.0057. (B) ***P = 0.0004, ****P < 0.0001. (C) **P= 0.0075, ****P < 0.0001. (D to F) 
The differences between WT and Ifnlr1−/− cells were not statistically significant (two-way 
ANOVA).
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Fig. 3. Viral burden in WT and Ifnlr1−/− mice
(A to I) Nine- to 12-week-old mice were infected with 102 plaque-forming units (PFU) of 
WNV via subcutaneous injection (A to F) or 101 PFU via intracranial injection (G to I). (A 
and B) Viral RNA was measured by qRT-PCR. (C to F) Viral titers were measured by 
plaque assay. Symbols represent individual mice from several independent experiments; 
bars indicate the mean of 5 to 15 mice per group. (G to I) Viral infection in CNS tissues was 
measured by plaque assay. Bars indicate the mean of five to six mice per group from two 
independent experiments. Dotted lines represent the limit of sensitivity of the assay. Viral 
titers in WT and Ifnlr1−/− mice were compared by the Mann-Whitney test (A to F) or t test 
(G to I). (E) *P = 0.0124, **P = 0.0045. (F) **P = 0.0031.
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Fig. 4. Cellular immune responses in WT and Ifnlr1−/− mice
(A to T) Leukocytes were harvested from the spleen (A to J) and brain (K to T) 8 days after 
WNV infection. Cells were stained with antibodies against CD45, CD19, CD11b, CD11c, 
CD3, CD4, CD8, and granzyme B. Cells were either stained with a tetramer displaying the 
immunodominant WNV peptide (Db-NS4B) (E and O) or restimulated with NS4B peptide 
and then stained with antibodies against IFN-γ and TNF-α (G, H, Q, and R). Total numbers 
of the indicated cell populations are shown. IFN-γ and TNF-α production is expressed as 
geometric mean fluorescence intensity (GMFI). Symbols represent individual mice, and data 
are combined from two independent experiments. The differences between WT and Ifnlr1−/− 
mice were not significant (Mann-Whitney test). Representative flow cytometry plots 
showing CD8+ and NS4B+ cells (I and S) or CD8+ and IFN-γ+ cells (J and T). Numbers 
indicate the percentage of cells in each quadrant, and the results are representative of two 
independent experiments.
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Fig. 5. BBB permeability in infected WT and Ifnlr1−/− mice
WT and Ifnlr1−/− mice were infected via a subcutaneous route with WNV or diluent (mock). 
(A to C) BBB permeability was assessed at 4 days after infection by measuring the 
accumulation of sodium fluorescein dye in CNS tissues after intraperitoneal administration. 
Symbols represent individual animals from two independent experiments. ****P < 0.0001 (t 
test). (D and E) Brain sections were stained to detect endogenous IgG leakage into the CNS 
parenchyma (shown in green); nuclei are shown in blue. Representative images were taken 
at×40 magnification (scale bars, 100 mm). (E) IgG staining was quantified from two fields 
from three mice per group and compared by t test. Cortex: *P = 0.0263; cerebellum: *P = 
0.0241.
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Fig. 6. IFN-λ increases TEER in BMECs
(A and B) Expression of Ifnar1, Ifnlr1, and Il10rb was measured by qRT-PCR from WT 
uninfected BMECs and astrocytes. Gene expression was normalized to 18S rRNA. (C and 
D) BMECs and astrocytes prepared from WT and Ifnlr1−/− mice were infected with WNV, 
and viral replication was measured by focus-forming assay (expressed as focus-forming 
units per milliliter). Results represent means ±SEM of nine samples from three experiments. 
The differences between WT and Ifnlr1−/− cells were not significant (two-way ANOVA). (E 
to I) WT or Ifnlr1−/− BMECs were cultured on Transwell inserts with astrocytes prepared 
from WT (E, left; and F to I) or Ifnlr1−/−(E, right) mice. Results represent means ± SEM of 
nine samples from two experiments. (E) BMECs were infected with WNV, and TEER was 
measured 6 hours later. WNV-infected WT BMECs were compared to Ifnlr1−/− BMECs (t 
test). ****P < 0.0001, ***P = 0.0006. (F) BMECs were treated with murine IFN-β or IFN-
λ3, and TEER was measured 6 hours later. WT BMECs were compared to Ifnlr1−/− BMECs 
(t test). IFN-β and IFN-λ (10 ng/ml): ****P < 0.0001. IFN-λ (100 ng/ml): ***P = 0.0003. 
(G) BMECs were pretreated with an IFNAR-blocking or isotype control monoclonal 
antibody (MAb) and then infected with WNV. TEER was measured 6 hours after infection. 
WT BMECs were compared to Ifnlr1−/− BMECs (t test). ****P < 0.0001. (H) WT BMECs 
were pretreated with cycloheximide (CHX) (20 μg/ml) for 18 hours and then infected with 
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WNV or treated with murine IFN-β (10 ng/ml) or IFN-λ3 (100 ng/ml). TEER was measured 
6 hours later. CHX-treated BMECs were compared to media-treated cells (t test). ****P < 
0.0001, *P = 0.009. (I) BMECs were prepared from WT and Stat1−/− mice and treated with 
murine IFN-β or IFN-λ3, and TEER was measured 2, 6, and 12 hours after treatment. 
Results represent means ± SEM of six samples from two experiments. IFN-treated BMECs 
were compared to vehicle-treated cells of the same genotype at 2 hours after treatment (t 
test). IFN-β: ***P = 0.0005 (WT), ***P < 0.0001 (Stat1−/−). IFN-λ: *P = 0.0204 (WT), *P 
= 0.0347 (Stat1−/−). WT and Stat1−/− cells were compared by two-way ANOVA. IFN-β: *P 
= 0.0311. (J) HCMEC/D3 cells were cultured on Transwell inserts and treated with human 
IFN-β (10 ng/ml) or pegylated human IFN-λ1 (100 ng/ml), and TEER was measured. 
Results represent means ± SEM of eight samples from two experiments. IFN-treated cells 
were compared to vehicle-treated cells at 2 hours after treatment (t test). IFN-β: ****P < 
0.0001. IFN-λ: **P = 0.0011. IFN-β– and IFN-λ–treated cells were compared by two-way 
ANOVA. ***P = 0.0006. (K and L) HCMEC/D3 cells were pretreated for 18 hours with 
LPS (100 ng/ml) or media as control, followed by pegylated human IFN-λ1 (100 ng/ml) for 
6 hours (or media). The cells were then infected with WNV at an MOI of 0.01 from the 
upper chamber. TEER was measured over the course of the experiment (K); at 6 hours after 
infection, virus crossing into the lower chamber was measured by qRT-PCR (L). Results 
represent means ± SEM of 12 samples from three experiments. (K) IFN-λ treatment was 
compared to media or LPS treatment by two-way ANOVA (K) or t test (L). ****P < 0.0001, 
**P = 0.0047.
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Fig. 7. Cell junction protein localization in endothelial cells
(A and B) WT BMECs were pretreated for 18 hours with LPS (100 ng/ml) and subsequently 
treated with murine IFN-λ3 (100 ng/ml) for 6 hours. (C) WT mice were treated with LPS (3 
mg/kg via an intraperitoneal route), LPS and pegylated murine IFN-λ2 (25 μg via 
intravenous route), or phosphate-buffered saline (PBS) alone. (A to C) Cells and brain 
sections were costained for the cell junction proteins ZO-1 (green) and claudin-5 (red); 
nuclei are shown in blue. Images were taken by confocal microscopy at ×63 magnification 
(scale bars, 20 mm). Arrows indicate ZO-1 and claudin-5 colocalization at intact tight 
junctions. Results are representative of two independent experiments. (B) Colocalization of 
ZO-1 and claudin-5 staining was determined using ImageJ software and compared by t test. 
Media versus IFN-λ: **P = 0.0033. LPS versus LPS + IFN-λ: **P = 0.0014.
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Fig. 8. IFN-λ enhances BBB tightness and restricts WNV neuroinvasion
(A to C) Eight-week-old WT mice were treated with LPS, LPS and pegylated murine IFN-
λ2 (25 mg via intravenous route), or PBS alone. BBB permeability was assessed 24 hours 
later by fluorescein or IgG permeation as described for Fig. 5. Symbols represent individual 
animals from two independent experiments. Values for LPS-treated mice were compared to 
mice receiving LPS + IFN-λ (t test). (A) Cortex: ****P < 0.0001, cerebellum: **P = 0.0096, 
spinal cord: **P = 0.0082. (C) Cortex: *P = 0.0348, cerebellum: *P = 0.0168. (D and E) 
Five-week-old WT mice were infected with 102 PFU of WNV via a subcutaneous route. On 
the day of infection and at days 2 and 4 afterward, 20 μg of pegylated murine IFN-λ2 protein 
(or PBS) was administered via an intravenous route. (D) Viral RNA in the plasma was 
measured on days 2 and 4 after infection. (E) Survival was monitored for 21 days after 
infection. n = 22 mice, *P = 0.0264 (log-rank test). (F and G) Nine-week-old WT mice were 
infected with 102 PFU of WNV via a subcutaneous route. At days 2, 3, and 4, 25 μg of 
pegylated murine IFN-λ2 protein (or PBS) was administered via an intravenous route. (F) 
Viral RNA in the plasma was measured on days 3,4, and5. (G) Viral burdeninthe CNS was 
measured by plaque assayatday 8. Symbols represent individual animals. Dotted lines 
represent the limit of sensitivity of the assay. ***P = 0.0009 (Mann-Whitney test).
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